Meeting
2021 Gastrointestinal Cancers Symposium
Phase II trial of the CDK4/6 inhibitor abemaciclib in patients (pts) with advanced and refractory well‐differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs).
Authors
Kit Man Wong
University of Washington/Seattle Cancer Care Alliance, Seattle, WA
Kit Man Wong , Bojana Irene Askovich , Harini Ramachandran , Jeniece Hensel , Susan Ottermiller , Annie Alidina , Reina Hibbert , Andrew L. Coveler , John A. Thompson , Elena Gabriela Chiorean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Neuroendocrine/Carcinoid
Track
Neuroendocrine/Carcinoid
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03891784
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS376)
DOI
10.1200/JCO.2021.39.3_suppl.TPS376
Abstract #
TPS376
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II randomized study to compare abemaciclib plus trastuzumab with or without fulvestrant to standard of care chemotherapy plus trastuzumab in hormone receptor positive, HER2-positive advanced breast cancer (monarcHER).
First Author: Sara M. Tolaney
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment.
First Author: Seth Andrew Wander
Poster
2023 ASCO Annual Meeting
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
First Author: Jesús Fuentes Antrás